KNSAKiniksa Pharmaceuticals International, plc
Is the business good?
A genuinely good business: earnings fully cash-backed (2.6×) and margins widening.
Operating profit is fully backed by cash.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
A balanced mix of margins, efficiency, and leverage. ROE 8% = margin × turnover × leverage.
Unless marked, from derived.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is KNSA?
Kiniksa Pharmaceuticals International, plc earns 54% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
Return on invested capital · cost of capital 9.0% · 45 points above what the capital costs: growth creates value
- Operating margin
- 12%
Operating margin · Drug Manufacturers - Specialty & Generic median 11% · 12 months to Q1 2026
- Cash conversion
- 2.58×
Cash conversion · operating cash flow covers the operating profit after tax
- Share count, year on year
- +8.2%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2021 | −406% |
| FY2022 | 4.4% |
| FY2023 | −9.3% |
| FY2024 | −11% |
| FY2025 | 11% |
Details›
- Gross margin12 months to Q1 2026
- 89%
- Operating margin12 months to Q1 2026
- 12%
- Net margin12 months to Q1 2026
- 9.7%
- Free cash flow margin
- 22%
- R&D as % of revenue
- 14%
- Revenue, trailing twelve months
- $754M
- Free cash flow, trailing twelve months
- $164M
- Net income, trailing twelve months
- $73M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 54%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Drug Manufacturers, Specialty & Generic
Ranks #28 of 41 by RyuScore